Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of HIFAS MENOPAUSE on Quality of Life in Postmenopausal Women
Sponsor: Hifas da Terra S.L.
Summary
This single-center, single-group, open-label study evaluated changes in menopause-related quality of life and menopausal symptoms in postmenopausal women aged 40 to 60 years after 24 weeks of treatment with HIFAS MENOPAUSE. Participants took two capsules of HIFAS MENOPAUSE orally once daily while fasting for 24 weeks. Study assessments were performed at baseline and after 4, 12, and 24 weeks of treatment. The primary objective was to evaluate change in menopause-related quality of life using the short-form Cervantes Scale. Additional assessments included menopausal symptom severity, weekly hot-flash frequency, difficulty concentrating, vulvovaginal health, vaginal pH, cytological maturation, treatment adherence, tolerability, satisfaction, and adverse events.
Official title: Evaluación de la Eficacia Del Uso de "HIFAS MENOPAUSE" en la Calidad de Vida de Mujeres Postmenopáusicas
Key Details
Gender
FEMALE
Age Range
40 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2025-02-14
Completion Date
2026-01-14
Last Updated
2026-08-11
Healthy Volunteers
No
Conditions
Interventions
HIFAS MENOPAUSE
HIFAS MENOPAUSE is a symbiotic dietary supplement administered as two oral capsules once daily while fasting for 24 weeks. Each daily dose contained Hericium erinaceus fruiting body powder 280 mg, Cordyceps sinensis mycelial extract 240 mg, Ganoderma lucidum fruiting body extract 100 mg, ashwagandha root extract 100 mg, green tea leaf extract 100 mg, a probiotic blend containing Bifidobacterium lactis, Lactobacillus plantarum, Bifidobacterium infantis, Lactobacillus acidophilus, and Bifidobacterium longum, as well as zinc, vitamin B6, vitamin A, and vitamin D. The study product was provided by Hifas da Terra, S.L.
Locations (1)
Instituto Palacios, Salud y Medicina de la Mujer
Madrid, Madrid, Spain